In Huntington disease (HD), hypothalamic neuropeptidergic systems are not equally affected at the peptide and mRNA levels. Because prohormone convertases (PCs) are critically involved in the conversion of propeptides into their active forms, we postulated that a decrease in PC expression may underlie these discrepancies. Therefore, we assessed the expression of PC1/3 and PC2 in the hypothalamic infundibular, suprachiasmatic, and paraventricular nuclei in postmortem tissues of HD patients and controls (n = 9, each) using immunocytochemistry and quantitative reverse transcription polymerase chain reaction. We also assessed PC1/3 and PC2 mRNA expression in the inferior frontal gyrus and colocalization of both PCs with corticotropin-releasing hormone and >-melanocyte-stimulating hormone. In HD patients, PC1/3 and PC2 expression was decreased in the hypothalamic infundibular (both p = 0.046) and paraventricular nuclei (p = 0.031 and p = 0.019). In the suprachiasmatic nucleus, PC1/3 and PC2 expressions were not different between HD and control cases; PC1/3 and PC2 mRNA levels in the inferior frontal gyrus were also not different. None of the PCs was colocalized with corticotropin-releasing hormone, whereas >-melanocyte-stimulating hormone showed colocalization with PC1/3 and PC2. These data suggest that defects in the processing of hypothalamic neuropeptides in HD may partially arise from decreased PC1/3 and PC2 expressions. These changes might contribute to selective neuropathology underlying various clinical manifestations and may provide novel therapeutic targets in HD patients.
INTRODUCTION
Patients with Huntington disease (HD) have a high prevalence of circadian, neuroendocrine, and autonomic disorders (1) that, for the most part, seem to be related to hypothalamic pathology (2Y6). We recently demonstrated that several neuropeptide populations in the suprachiasmatic (SCN), infundibular (INF), and paraventricular (PVN) nuclei are affected in HD. Interestingly, many of these neuropeptidergic systems showed decreases at the peptide level, whereas mRNA levels were often normal. This was the case, for example, for arginine vasopressin and vasoactive intestinal polypeptide in the SCN. Sometimes, as was the case for neuropeptide Y in the INF, the mRNA levels were even markedly increased (4Y6). Even when peptide levels were not different from controls, an increase in mRNA levels was observed for some neuropeptides in HD, as was the case for corticotropin-releasing hormone (CRH) in the PVN. The discrepancies between peptide and mRNA levels suggest the presence of a posttranscriptional or posttranslational processing abnormality. Because prohormone convertases (PCs) play a crucial role in the conversion of propeptides into active neuropeptides (7Y9), peptide-mRNA discrepancies might be explained by a decrease in PC levels in different hypothalamic nuclei.
In the hypothalamus, PC1/3 expression occurs mainly in the supraoptic nucleus, SCN, and PVN, but also in the INF (7, 8) , whereas expression is more widespread and is localized, for example, in the SCN, INF, PVN, supraoptic, and periventricular nuclei (7, 9) . Prohormone convertase 1/3 colocalizes with arginine vasopressin (AVP)Yexpressing neurons in the SCN, whereas PC2 shows a distribution similar to vasoactive intestinal polypeptide (VIP) in the SCN (7) . In HD patients, we found that neuropeptide Y was decreased in the INF at the peptide level whereas it was markedly increased at the mRNA level (6) . Interestingly, both PC1/3 and PC2 seem to be involved in the conversion of proYneuropeptide Y to neuropeptide Y (10) . Similarly, in the PVN of HD patients, we observed normal levels of CRH at the peptide level, whereas mRNA levels were significantly increased (5) . Moreover, in HD patients, there was a similar discrepancy between the numbers of AVP-and VIP-immunoreactive (ir) neurons in the SCN; both were significantly reduced but their respective mRNA levels were unaltered (4) .
To assess whether a decrease in PC expression might underlie a defect in the processing of several hypothalamic neuropeptides in HD patients, we assessed the expression of 2 major PCs, that is, PC1/3 and PC2, in the hypothalamus of HD patients and controls. Expression of both of these PCs was studied in the SCN, INF, and PVN. In addition, to determine whether changes were also present in extrahypothalamic areas, we also compared PC1/3 and PC2 mRNA levels in the inferior frontal gyrus (IFG) of HD patients and controls.
MATERIALS AND METHODS

Postmortem Material
Paraffin-embedded hypothalamic tissue and snap-frozen material from a total of 9 HD patients and an equal number of control subjects matched for sex, age, clock time and month of death, postmortem delay, and fixation time was obtained through the Netherlands Brain Bank (NBB). Different control subjects were used for each analysis when hypothalamic and frozen tissue were not available from the same patient while maintaining adequate matching for possible confounding factors. Characteristics for all patients and control subjects used for each analysis are shown in Table 1 and Table, Supplemental Digital Content 1, http://links.lww.com/NEN/A531. Written informed consent for a brain autopsy, the use of brain material, and the use of medical records for research purposes was acquired by the NBB from patients or their next of kin. For the PVN and IFG, 9 HD patients and control subjects were analyzed; for analysis of the INF and SCN, 8 HD patients and 8 control subjects were available.
The diagnosis of HD was clinically and neuropathologically confirmed in all patients. In addition, the diagnosis was genetically confirmed (CAG repeat Q39) in all but 1 HD patient (NBB 92Y105). The latter patient, however, had a positive family history, the clinical features of HD, and confirmed Vonsattel grade II HD neuropathology (11) . Exclusion criteria for control subjects were primary neurologic and/or psychiatric disorders and, for both HD patients and control subjects, glucocorticoid therapy during the last 2 months before death.
Immunocytochemistry
The immunocytochemical procedures for PC1/3 and PC2 (antibodies obtained from W. van de Ven, MD, PhD, University of Leuven, Belgium, and kindly donated by F. van Leeuwen, PhD) have been described (8) . Hypothalamic tissue was fixed in formalin, embedded in paraffin, and serially cut into 6-Km-thick sections. Briefly, every 100th 6-Km-thick section of the PVN and INF and every 25th section for the SCN were mounted on Superfrost Plus slides (Menzel, Braunschweig, Germany) and dried for 2 days at 37-C. Sections were deparaffinized in xylene and rehydrated in graded ethanols. In addition, sections for PC2 analysis were preincubated in Trisbuffered saline ([TBS] 0.05 mol/L Tris and 0.15 mol/L NaCl; pH 7.6) with 3% (wt/vol) milk (Elk Campina, Eindhoven, Netherlands). Next, the sections were incubated in rabbitYantihuman PC1/3 antibody (8) 1:15,000 or rabbitYanti-human PC2 antibody (8) 1:1000 in SUMI (0.25% gelatin, 0.5% Triton X-100, 0.05 mol/L Tris, and 0.15 mol/L NaCl; pH 7.6). After overnight incubation at 4-C, sections were further incubated in biotinylated goatYanti-rabbit IgG (Vector Laboratories Inc., Burlingame, CA) 1:400 in SUMI and afterward in ABC complex (Vector Laboratories Inc.) 1:800 in SUMI. Visualization of the immunoreaction product was achieved by incubation in 3,3 ¶-diaminobenzidine (Sigma, St. Louis, MO) and 0.5 mg/mL TBS, containing 0.23% (wt/vol) nickel ammonium sulfate (Merck) and 0.01% (vol/vol) H 2 O 2 (Merck). The antibody specificity tests for PC1/3 and PC2 have been described (8) . Specificity of the PC1/3 and PC2 antibodies in the Western blot assay was positive for AtT20 cell lysate and negative for bacterial fusion proteins with parts of PC4, PACE4, PC6A, the C-terminus of PC6B, and the prodomain of furin. Moreover, the PC1/3 antibody was negative for bacterial fusion proteins with parts of PC2 and the PC2 antibody negative for fusion proteins with parts of PC1/3 (8) . Both antibodies were positive in immunoprecipitation and immunofluorescence in AtT20 cells as endogenous activity in PC1/3-or PC2-transfected cells and negative in COS-1 cells. Staining of hypothalamic sections after adsorption of the antibodies with their respective recombinant antigens and omission of the primary antibodies did not produce any signal (8) .
Quantification
For an estimation of total numbers of PC1/3-and PC2-ir neurons in SCN, PVN, and INF for each subject, every 100th (6-Km-thick) section throughout the PVN and INF and every 25th section throughout the SCN in rostrocaudal direction were used for analysis. All analyses were performed on the left half of the hypothalamus for all subjects. Estimates were made using an image analysis system (ImagePro version 4.5, Media Cybernetics, Silver Spring, MD) connected to a camera (JVC KY-F553CCD) and plain objective microscope (Zeiss Axioskop with Plan-NEOFLUAR Zeiss objectives, Carl Zeiss GmbH, Jena, Germany). Analysis consisted of 2 steps: 1) area selection of the entire nucleus of interest (i.e. the SCN, PVN, or INF) and determining the number of all immunoreactive neurons with a visible nucleolus within the area of interest, serving as a unique marker for individual neurons; and 2) determination of the number of neuropeptide-ir neurons. Area selection and sampling were performed with a 2.5Â objective, and the image was loaded into the image analysis system and displayed on the monitor. Position and scanning stage using x and y coordinates were stored. In this image, the area covered by the entire SCN, INF, and PVN was manually outlined, and over this outlined area, a grid was superimposed. From the respective grid fields, x and y coordinates were stored and all individual images were randomly retrieved at 40Â objective on the image analysis monitor. The manually outlined borders of the SCN, INF, and PVN area were visible in these images, and each neuropeptide-ir neuron containing a nucleolus was counted within these borders. This method has been described (4Y6).
The total number of SCN, PVN, and INF neurons in one half of the hypothalamus for each neuropeptide was estimated using a previously described technique based on multiplication of the neuronal counts by sample frequency (interval distance between sections) of the hypothalamus not requiring cross-sectional area measurements. These methods were based on the Cavalieri principle. Briefly, the amount of immunoreactive neurons per section, defined as A n , was used for estimating the number of neurons within the nonassessed sections on either side of A n , defined as D n . The latter was calculated by adding the section number (d n ) of A n to the section number of the previous section (d n-1 ) and dividing it by 2. The same procedure was repeated for the consecutive section (d n+1 ), and both figures were combined, so 
Colocalization
Processing of sections used for colocalization was identical to that described in the immunocytochemistry section up to preincubation. Colocalization was performed for CRH and PC1/3 or PC2, as well as for >-melanocyte-stimulating hormone (>-MSH) and PC1/3 or PC2. Sections for PC2-CRH colocalization were pretreated in TBS with 1% milk (wt/vol; Elk, Campina); sections for PC1/3-CRH were not pretreated. Next, the sections were incubated in rabbitYanti-human PC1/3 antibody (8) 1:15,000 or rabbitYanti-human PC2 antibody (8) 1:1000 both together with ratYanti-human CRH antibody (PFU 83, 1:100,000 in SUMI [PC1/3] or in SUMIY1% milk [PC2]; Netherlands Institute for Neuroscience [5] ). After overnight incubation at 4-C, sections were washed in TBS twice. Sections were then incubated with alkaline phosphataseYconjugated donkeyYanti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc, West Grove, PA) 1:200 together with biotinylated antirat IgG (Vector Laboratories Inc.) 1:400 in SUMI. Visualization of the alkaline phosphatase immunoreaction product was achieved by incubation in NBT (Sigma)-BCIP (Roche) coloring solution (337.5 Kg/mL nitro blue tetrazolium chloride, 175.4 Kg/mL 5-bromo-4-chloro-3-indolyl phosphate, toluidine salt, 240 Kg/mL levamisole in 100 mmol/L Tris-HCl pH 9.5, 100 mmol/L NaCl, 5 mmol/L MgCl 2 ) at room temperature in the dark for 25 minutes. Reaction was halted with sterile water, and sections were first washed in 100% methanol for 5 minutes, followed by 2 rinses in TBS. Sections were then incubated in ABC complex (Vector Laboratories Inc.) for 1 hour at RT, followed by 2 rinses in TBS. Subsequently, sections were equilibrated for 5 minutes in acetic acid buffer (29.6 mmol/L acetic acid, 70.4 mmol/L sodium acetate, pH 5.0) and then developed in AEC solution (0.05% [wt/vol] 3-amino-9-ethylcarbazole in acetic acid buffer, 0.015% H 2 O 2 ) for approximately 15 minutes, washed in TBS, and finally coverslipped in Mowiol.
The treatment of sections for PC1/3 and PC2 colocalization with >-MSH was identical to the procedure previously described, except for the pretreatment that consisted of microwave oven incubation for 10 minutes in TBS at full power (800 W); the sections for PC2 analysis were additionally preincubated in TBS with 1% (wt/vol) milk. Sections were incubated in PC2 and PC1/3 antibody, together with sheepYanti-human >-MSH antibody (Ab5087; Chemicon International Inc., Temecula, CA [6] ) 1:100,000 in SUMI (PC1/3) or in SUMIY1% milk (PC2). Finally, the secondary antibody consisted of a rabbitYanti-sheep IgG antibody (Vector Laboratories Inc.).
Additional colocalizations were not performed because the PC1/3 and PC2 antibodies, as well as the antibodies previously used for neuropeptide analysis in the PVN, INF, and SCN, were all raised in rabbits (4Y6).
Quantitative Polymerase Chain Reaction
All methods for snap-frozen tissue dissection, RNA isolation, cDNA synthesis, and quantitative polymerase chain reaction (PCR) have been described (3, 12) . RNA quality of all samples was sufficient for quantitative real-time PCR analysis (RNA integrity number, Q5.70 [13] ; Table 1 ). Forward (F) and reverse (R) primer sequences and GenBank accession numbers for PC1/3 and PC2 were as follows: F 5 ¶-TTTGCCCACTCCTACACTAAG-3 ¶, R 5 ¶-TCCTGCCTAACAGAAGATGC-3 ¶ and NM_00439.4 for PC1/3; F 5 ¶-AACGACCCCTATCCTTACC-3 ¶, R 5 ¶-ATGCTACTCCAACTCCACAG-3 ¶ and NM_002594.2 for PC2. Actin-A, hydroxymethylbilane synthase, hypoxanthine phosphoribosyltransferase 1, tubulin-> (TUB>), and TUBA4 were used as reference genes, and their respective primer sequences have been described elsewhere (14) . To correct for sampling-related differences such as RNA quality and RNA quantity, the normalization strategy from Wang et al (14) was used. The normalization factor consisted of the geometric mean of actin-A, hydroxymethylbilane synthase, hypoxanthine phosphoribosyltransferase 1, TUB>, and TUBA4. The linearity of each qPCR assay was determined on serial dilutions of cDNA pooled from all subjects.
Statistical Analysis
All data are presented as mean T SEM unless otherwise specified. Differences between groups were statistically evaluated by the nonparametric Mann-Whitney U test (2-tailed). Intergroup differences in clock time and month of death were evaluated using the Mardia-Watson test. Spearman Q was used to assess all correlations; p G 0.05 was considered to be significant. All statistical analyses were performed using SPSS Statistics 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
Control subjects did not differ from HD patients for any of the putative confounders, that is, sex, age, clock time and month of death, postmortem delay, and fixation time ( 
Immunocytochemistry
Representative immunocytochemical stainings for PC1/3 and PC2 are provided in Figures 1 and 2 , respectively. Expression of both PCs was observed in the SCN, INF, PVN, supraoptic nucleus (SON), and SON accessory nuclei. No staining was observed in the ventromedial or dorsomedial nucleus or periventricular area. Both PCs were only localized in the cytoplasm of neurons and within their fibers. Fibers were observed mainly in the INF, projecting to the median eminence, and projecting from the PVN to the neurohypophysis.
The number of PC1/3-ir neurons in the INF of HD patients (10,505 T 4,956; n = 8) was 50% less than that in control subjects (21,126 T 12,471; n = 8) (p = 0.046) (Fig. 3) . Similarly, the number of PC2-ir neurons in the INF was reduced by 45% in HD patients (9,775 T 4,157; n = 8) versus control subjects (17,860 T 7,348; n = 8) (p = 0.046) (Fig. 3) .
In the PVN, the number of PC1/3-ir neurons was 22% lower in HD patients (93,290 T 19.681; n = 9) versus control subjects (119,787 T 27,819; n = 9) (p = 0.031) (Fig. 4) . Prohormone convertase 2Yimmunoreactive neuronal numbers were decreased by 39% in HD patients (28,645 T 9,901; n = 9) versus control subjects (47,178 T 20.783; n = 9) (p = 0.019) (Fig. 4) .
The number of PC1/3-ir neurons in the SCN of HD patients (3,614 T 2,235; n = 8) was not different from that in control subjects (4,803 T 1,744; n = 8) (p = 0.29). Likewise, the number of PC2-ir neurons in the SCN was not different between HD patients (5,162 T 3,624; n = 8) and control subjects (6,233 T 3,168; n = 8) (p = 0.53) (Fig. 5 ).
An overview of neuropeptidergic changes in previous studies (4Y6) and of the current findings is provided in Table 2 . Table 3 shows the results of assessment of colocalization. Corticotropin-releasing hormone in the PVN was not colocalized with PC1/3 or PC2. Alpha-melanocyte-stimulating hormone was colocalized in INF neurons in 5 of 8 subjects with PC1/3 and in 3 of 8 subjects with PC2.
Colocalization
Inferior Frontal Gyrus
Levels of mRNA, expressed in arbitrary units, of both PC1/3 and PC2 were not significantly different in the cortical IFG of HD patients (0.033 T 0.025 and 0.032 T 0.025, respectively) (n = 9) versus control subjects (0.015 T 0.008 and 0.014 T 0.007, respectively) (n = 9) (p = 0.67 and p = 0.80, respectively).
Correlations
In HD patients, the number of INF PC1/3-ir neurons correlated positively with the number of INF NPY-ir neurons from a previous study (Q = 0.786, p = 0.021) (6), whereas in control subjects, the number of PC1/3-ir neurons correlated with INF NPY mRNA levels (Q = 0.821, p = 0.023). In the INF, the number of PC1/3-ir neurons also tended to be positively correlated with the number of agouti-related peptide-ir and cocaine-and amphetamine-regulated transcript-ir neurons in control subjects (Q = 0.67, p = 0.07 and Q = 0.64, p = 0.09, respectively) (6) . The number of PC2-ir neurons showed a positive trend with agouti-related peptide-ir neurons in control subjects (Q = 0.64, p = 0.09).
In the PVN of control subjects, the number of PC2-ir neurons correlated positively with the number of AVP-ir neurons in this nucleus, as assessed in a previous study (Q = 0.667, p = 0.05) (5), whereas in HD patients, there was a positive trend (Q = 0.60, p = 0.09).
In the SCN of control subjects, the number of VIP-ir neurons correlated positively with the number of PC2-ir neurons (Q = 0.886, p = 0.019), whereas AVP-ir neurons and VIP mRNA levels tended to positively correlate with the number of PC2-ir neurons (both Q = 0.77, p = 0.07) (4) . No correlations were observed in the SCN data of HD patients (4) .
In HD patients, no correlations were observed between disease duration or mutant HTT CAG repeat length and any of the PC1/3 or PC2 outcome measures (p Q 0.17), except between the number of PC1/3-ir neurons in the PVN and mutant HTT CAG repeat length (Q = 0.755, p = 0.031).
DISCUSSION
Findings concerning hypothalamic neuropeptides in HD patients have suggested the presence of a processing defect between mRNA and propeptides and/or their active peptide forms (4Y6). In the current study, we showed an area-specific decrease in hypothalamic PC1/3 and PC2 expressions, providing an explanation for this potential processing defect at least for a number of hypothalamic neuropeptides in several areas. We observed a significant decrease of 50% in PC1/3-ir and 45% in PC2-ir neurons in the INF and a 22% decrease in PC1/3-ir and 39% in PC2-ir neurons in the PVN of HD patients. In the SCN, however, the numbers of PC1/3-ir and PC2-ir neurons were unchanged. Furthermore, we observed no change in PC expression in the IFG of HD patients. These data show that the decrease in PC1/3 and PC2 is brain area and hypothalamic nucleus specific.
The marked reduction of PC1/3 and PC2 expression in the INF of HD patients likely plays a role in the reduction of the number of NPY-ir neurons in this nucleus despite a threefold increase of NPY mRNA levels (6) . Both PCs have a role in converting proNPY to NPY, although P1/3 appears to be more potent than PC2 (10). This notion is further supported by our findings of a significant positive correlation between the number of PC1/3-ir neurons and NPY-ir neurons in HD patients, as well as a positive correlation between the number of PC1/3-ir neurons and NPY mRNA levels in control subjects. At the peptide level, other neuropeptide populations in the INF seem to be unaffected in HD, as the number of agouti-related peptide-, cocaine-, and amphetamine-regulated transcript and >-MSH-ir neurons in the INF of HD patients was unchanged (6) . However, the mRNA levels of these neuropeptides have not been assessed so far. ProCART is processed by PC1/3 to CART (15) and proopiomelanocortin (POMC) into >-MSH by PC1/3 and PC2 (16, 17) , which is in agreement with our observation that CART and agouti-related peptide both showed a tendency to correlate with PC1/3. Future studies should focus on the extent to which decreases in PC1/3 and PC2 expression in the INF may interfere with the processing of these 2 neuropeptides and whether compensatory increases in mRNA levels might account for the unchanged numbers of CART-ir and >-MSH-ir neurons. At least for >-MSH, an alternative explanation might lie in the fact that, in comparison with NPY, FIGURE 1. Representative immunocytochemical staining for prohormone convertase 1/3 (PC1/3). In Huntington disease (HD) patients (A), the number of PC1/3-immunoreactive (ir) neurons in the infundibular nucleus is significantly lower than that in control subjects (B) (p = 0.046). In the paraventricular nucleus, HD patients (C) also had fewer PC1/3-ir neurons than those in control subjects (D) (p = 0.031). In the suprachiasmatic nucleus, the number of PC1/3-ir neurons was not different between an HD patient (E) and a control subject (F). Scale bars = (AYD) 500 Km; (E, F) 250 Km; bars in the inserts represent 25 Km. HD patient NBB 99Y120 and control subject NBB 93-060 are illustrated.
a decrease in its expression is more difficult to detect because >-MSH antibodies obligatorily also recognize its precursor protein, POMC (18) . In addition, our results seem to indicate that, unlike in rodents, neither PC1/3 nor PC2 has a role in converting POMC to >-MSH in the human hypothalamus (19) , making >-MSH an interesting target for further studies in humans.
Prohormone convertase 1/3Yknockout mice show a strong reduction in CART levels (15) ; therefore, the decrease in the number of PC1/3-ir neurons in the PVN may, at least partly, account for the finding that the number of CART-ir neurons tended to be lower in HD patients (5) . Whether the decrease in PC1/3 and PC2-ir neurons also affects other PVN neuropeptide populations in HD, such as the AVP and oxytocinexpressing neurons, remains to be shown because both neuropeptides were only studied at the peptide level and not at the mRNA level (5, 20) . The number of AVP, oxytocin, and thyrotropin-releasing hormone neurons was unchanged in the PVN of HD patients (6) . Alternatively, it is also possible that mRNA levels of AVP in the PVN of HD patients may not be altered because of the functional redundancy of several PCs in converting proAVP to AVP (21) . Regarding the discrepancy FIGURE 2. Representative immunocytochemical staining for prohormone convertase 2 (PC2). In Huntington disease (HD) patients (A), the number of PC2-immunoreactive (ir) neurons in the infundibular nucleus was significantly less than those in control subjects (B) (p = 0.046). In the paraventricular nucleus, HD patients (C) had fewer PC2-ir neurons than those in control subjects (D) (p = 0.019). In the suprachiasmatic nucleus, the numbers of PC2-ir neurons were not different between HD patients (E) and control subjects (F). Scale bars = (AYD) 500 Km; (E, F) 250 Km; bars in the inserts represent 25 Km. HD patient NBB 99Y120 and control subject NBB 93Y060 are illustrated.
between the normal CRH peptide and high mRNA levels in HD patients (5), it seems that only the reduction in PC2-ir neurons may have an effect because PC1/3 is not expressed in parvocellular neurons (CRH and thyrotropin-releasing hormone expressing neurons) of the rat PVN (22) . Our results in the human hypothalamus, however, show no colocalization between PC1/3 or PC2 and CRH. This indicates that, in humans, unlike in rodents, processing of proCRH to CRH is not mediated by PC1/3 or PC2, making the CRH neurons of special interest for further research.
In the SCN of HD patients, the numbers of both VIPand AVP-expressing neurons were decreased, whereas their corresponding mRNA levels were unchanged. In addition, the numbers of melatonin receptor 1Y and 2Yexpressing neurons were unchanged (4) . The number of PC1/3 and PC2-ir neurons in the SCN of HD patients was unchanged, so the discrepancy between VIP and AVP peptide and mRNA levels (4) in this nucleus is unlikely to be caused by diminished PC1/3 and PC2 expression. Potentially, a disruption of other, yet unknown, PCs may provide an explanation. Alternatively, an increase in axonal transport in the SCN could be the underlying cause, particularly of AVP to the target sites of SCN, such as the subparaventricular zone or the dorsomedial nucleus (23) . A change in axonal transport has also been proposed for patients with a major depressive disorder in whom an opposite alteration was observed of AVP peptide and mRNA levels (24) . In addition, an increase in protein degradation or changes in mRNA instability could have played a role, not only in the SCN, but also in other hypothalamic nuclei; however, this possibility has not been studied in HD patients.
The reason for a decrease in hypothalamic PC1/3 and PC2 expression remains elusive. Although it is tempting to speculate that mutant huntingtin may interfere with normal PC functioning in HD patients, at this time, there is no evidence to support any interaction between normal or mutant huntingtin and PCs. Moreover, we did not observe a consistent association between mutant HTT CAG repeat length and the number of PC1/3-or PC2-ir neurons in the hypothalamic nuclei that were assessed. A significant correlation was observed only between the number of PC1/3-ir neurons in the PVN and mutant HTT CAG repeat length. Elevated serum cortisol levels in HD patients (2) might be responsible for a decrease in PC expression because glucocorticoid treatment decreases the number of both PC1/3-and PC2-ir neurons in the human PVN and SON (25) . In addition, the increase in serum leptin levels in HD (26, 27) may downregulate PC1/3 Data are expressed as mean numbers of immunoreactive neurons for each neuropeptide, except for mRNA levels, which are expressed as arbitrary units. The overlap in the number of subjects indicates the number of HD patients and control subjects that were used in the prohormone convertase analyses versus previous neuropeptide analyses (4Y6). Statistical analyses were performed using the Mann-Whitney U test; significant changes are indicated by *.
>-MSH, >-melanocyte-stimulating hormone; AgRP, agouti-related peptide; AVP, arginine vasopressin; CART, cocaine-and amphetamine-regulated transcript; CRH, corticotrophin-releasing hormone; HD, Huntington disease; ICC, immunocytochemistry; ISH, in situ hybridization; NPY, neuropeptide Y; OXT, oxytocin; PC, prohormone convertase; VIP, vasoactive intestinal polypeptide. Control subjects NBB 99Y080
-, no colocalization; T, weak colocalization; + strong colocalization. >-MSH, ?>-melanocyte-stimulating hormone; CRH, corticotrophin-releasing hormone; PC, prohormone convertase. expression in the INF, whereas its expression in the PVN is unlikely to be affected by leptin (28) . However, whether leptin levels remain high in end-stage HD patients is not known.
In conclusion, to our knowledge, this is the first study reporting a hypothalamic areaYspecific decrease in PC1/3 and PC2 levels in HD patients. These findings may at least partly account for the discrepancies between peptide and mRNA levels of several hypothalamic neuropeptides in patients with this disease. Furthermore, the unchanged expression of PC1/3 and PC2 in the cortical IFG of HD patients indicates that decreases in PC1/3 and PC2 levels are brain area specific.
